Advertisement

Médecine Intensive Réanimation

, Volume 26, Issue 1, pp 63–74 | Cite as

La Non Alcoholic Fatty Liver Disease (NAFLD) et la Non Alcoholic Steato-Hepatitis (NASH) des pathologies de système : revue pour le réanimateur

  • M. Hachemi
  • S. Benmakhlouf
  • P. Prost
  • N. Santolaria
  • X. Tchenio
  • N. Sedillot
  • F. Zoulim
Mise au Point / Update

Résumé

La NAFLD (Non Alcoholic Fatty Liver Disease) et la NASH (Non Alcoholic Steato-Hepatitis) sont des maladies de système avec une composante inflammatoire et sont intimement liées au syndrome métabolique, à l’insulinorésistance et à l’obésité. Les atteintes cardiovasculaires sont la première cause de morbimortalité dans la NAFLD, suivies des néoplasies puis des atteintes hépatiques. La recherche biopharmaceutique développe de nouvelles molécules afin de traiter et de reverser la NASH sans aggravation de la fibrose. La NAFLD est l’atteinte hépatique la plus fréquente dans les pays développés et va devenir la première cause de greffe hépatique aux États-Unis d’Amérique dans un avenir proche. Elle représente à ce titre un intérêt majeur pour le médecin réanimateur.

Mots clés

Non Alcoholic Fatty Liver Disease (NAFLD) Non Alcoholic Steato-Hepatitis (NASH) Syndrome métabolique Insulinorésistance Obésité Épidémiologie Elafibranor 

Non Alcoholic Fatty Liver Disease and Non Alcoholic Steato-Hepatitis are multisystemic diseases: Review for intensivists

Abstract

NAFLD and NASH are multisystemic disease linked to metabolic syndrom, insulin resistance and obesity. Cardiovascular abnormalities are common in NAFLD and are the principal cause of mortality in the disease, follow by neoplasia and liver complications. The biopharmaceutical research is developping new target in NASH with the aim of reversion NASH without worsening fibrosis. NAFLD is the most common cause of chronic liver disease in Western countries and should be the first indication for liver transplantation in near years in USA. NAFLD presents as such a major interest for the physician intensivist.

Keywords

Non Alcoholic Fatty Liver Disease (NAFLD) Non Alcoholic Steato-Hepatitis (NASH) Metabolic syndrom Insulin resistance Obesity Epidemiology Elafibranor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64: 73–84CrossRefPubMedGoogle Scholar
  2. 2.
    Buzzetti E, Pinzani M, Tsochatzis EA, (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65: 1038–1048CrossRefPubMedGoogle Scholar
  3. 3.
    Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592–1609CrossRefPubMedGoogle Scholar
  4. 4.
    Ahmed A, Wong RJ, Harrison SA, (2015) NAFLD review: Diagnosis, treatment and outcomes. Clin Gastroenterolo Hepatol 13: 2062–2070CrossRefGoogle Scholar
  5. 5.
    Bedossa P, (2016) Histological assessment of NAFLD. Dig Dis Sci 61: 1348–1355CrossRefPubMedGoogle Scholar
  6. 6.
    Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA, (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249–1253CrossRefPubMedGoogle Scholar
  7. 7.
    Patel YA, Berg CL, Moylan CA, (2016) Nonalcoholic Fatty liver disease: Key considerations before and after transplantation. Dig Dis Sci 61: 1406–1416CrossRefPubMedGoogle Scholar
  8. 8.
    Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A, (2016) Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31: 936–944CrossRefPubMedGoogle Scholar
  9. 9.
    Eckel RH, Alberti KG, Grundy SM, Zimmet PZ, (2010) The metabolic syndrome. The Lancet 375: 181–183CrossRefGoogle Scholar
  10. 10.
    Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Söderberg S, Alberti KG, Tuomilehto J, Chitson P, Shaw JE, (2008) Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity 16: 2707–2716CrossRefPubMedGoogle Scholar
  11. 11.
    Dhindsa S, Tripathy D, Sanalkumar N, RaviShankar S, Ghanim H, Aljada A, Dandona P, (2005) Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment. J Clin Endocrinol Metab 90: 5058–5063CrossRefPubMedGoogle Scholar
  12. 12.
    Mowery NT, Dortch MJ, Dossett LA, Norris PR, Diaz JJ Jr, Morris JA Jr, May AK, (2009) Insulin resistance despite tight glucose control is associated with mortality in critically ill surgical patients. J Intensive Care 24: 242–251CrossRefGoogle Scholar
  13. 13.
    Finney SJ, Zekveld C, Elia A, Evans TW, (2003) Glucose control and mortality in critically ill patients. JAMA 290: 2041–2047CrossRefPubMedGoogle Scholar
  14. 14.
    Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, (2003) Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31: 359–366CrossRefPubMedGoogle Scholar
  15. 15.
    Byrne CD, Targher G, (2015) NAFLD: a multisystem disease. J Hepatol 62: S47–S64CrossRefPubMedGoogle Scholar
  16. 16.
    Mantovani A, Ballestri S, Lonardo A, Targher G, (2016) Cardiovascular disease and myocardial abnormalities in nonalcoholic liver disease. Dig Dis Sci 61: 1246–1267CrossRefPubMedGoogle Scholar
  17. 17.
    Anstee QM, Targher G, Day CP, (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10: 330–344CrossRefPubMedGoogle Scholar
  18. 18.
    Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G, (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20: 1724–1745CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, Nasir K, (2008) Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 201: 1–7CrossRefPubMedGoogle Scholar
  20. 20.
    Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K, (2013) A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 230: 258–267CrossRefPubMedGoogle Scholar
  21. 21.
    Stepanova M, Younossi ZM, (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10: 646–650CrossRefPubMedGoogle Scholar
  22. 22.
    Arslan U, Türkoğlu S, Balcioğlu S, Tavil Y, Karakan T, Cengel A, (2007) Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 18: 433–436CrossRefPubMedGoogle Scholar
  23. 23.
    Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL, (2011) Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60: 1721–1727CrossRefPubMedGoogle Scholar
  24. 24.
    Kim D, Kim WR, Kim HJ, Therneau TM, (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57: 1357–1365CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, Vasan RS, Calderwood AH, Pencina M, Sullivan LM, Ellinor PT, Benjamin EJ, (2013) Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 111: 219–224CrossRefPubMedGoogle Scholar
  26. 26.
    Alonso A, Misialek JR, Amiin MA, Hoogeveen, RC, Chen LY, Agarwal SK, Loehr LR, Soliman EZ, Selvin E, (2014) Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 100: 1151–1156CrossRefGoogle Scholar
  27. 27.
    Ozveren O, Izgi C, Eroglu E, Simsek MA, Turer A, Kucukdurmaz Z, Cinar V, Degertekin M, (2016) Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty liver disease. Ultrason Imaging 38: 225–235CrossRefPubMedGoogle Scholar
  28. 28.
    Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Ho YL, Yang WS, Wu MS, Chen MF, (2015) Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 4: e001820Google Scholar
  29. 29.
    Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM, (2010) TNF-alpha and IL-1beta increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 47: 378–386CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E, (2011) Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 22: 660–670CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G, (1998) Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27: 28–34CrossRefPubMedGoogle Scholar
  32. 32.
    Bonapace S, Valbusa F, Bertolini L, Pichri I, Mantovani A, Rossi A, Zenari L, Barbieri E, Targher G, (2014) Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One 9: e88371CrossRefGoogle Scholar
  33. 33.
    Markus MR, Baumeister SE, Stritzke J, Dörr M, Wallaschofski H, Völzke H, Lieb W, (2013) Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol 33: 1690–1695CrossRefPubMedGoogle Scholar
  34. 34.
    Völzke H, Haring R, Lorbeer R, Wallaschofski H, Reffelmann T, Empen K, Rettig R, John U, Felix SB, Dörr M, (2010) Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 209: 606–610CrossRefPubMedGoogle Scholar
  35. 35.
    Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, Baik I, Lim HE, Kim EJ, Na JO, Lee JB, Lee SK, Shin C, (2014) Nonalcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100: 938–943CrossRefPubMedGoogle Scholar
  36. 36.
    Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S, (2006) Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40: 949–955CrossRefPubMedGoogle Scholar
  37. 37.
    VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ, (2015) Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 62: 773–783CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Granér M, Nyman K, Siren R, Pentikäinen MO, Lundbom J, Hakkarainen A, Lauerma K, Lundbom N, Nieminen MS, Taskinen MR, (2015) Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging 8: e001979Google Scholar
  39. 39.
    Rijzewijk LJ, Van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, De Roos A, Lamb HJ, (2008) Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52: 1793–1799CrossRefPubMedGoogle Scholar
  40. 40.
    Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, Ragogna F, Canu T, Scifo P, Del Mashio A, Luzi L, (2008) Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47: 51–58CrossRefPubMedGoogle Scholar
  41. 41.
    Fintini D, Chinali M, Cafiero G, Esposito C, Giordano U, Turchetta A, Pescosolido S, Pongiglione G, Nobili V, (2014) Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis 24: 72–74CrossRefPubMedGoogle Scholar
  42. 42.
    Sunbul M, Kivrak T, Durmus E, Akin H, Aydin Y, Ergelen R, Yilmaz Y, Agirbasli M, (2015) Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc Ther 33: 294–299CrossRefPubMedGoogle Scholar
  43. 43.
    Poloz Y, Stambolic V, (2015) Obesity and cancer, a case for insulin signaling. Cell Death and Disease 6: e2037CrossRefGoogle Scholar
  44. 44.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ, (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625–1638CrossRefPubMedGoogle Scholar
  45. 45.
    Angulo P, Kleiner De, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F, (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol 149: 389–397CrossRefGoogle Scholar
  46. 46.
    Arase Y, Suzuki F, Kobayashi M, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T, (2011) The development of chronic kidney disease in Japanese patients with nonalcoholic fatty liver disease. Intern Med 50: 1081–1087CrossRefPubMedGoogle Scholar
  47. 47.
    Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M, (2010) Relationship between kidney function and liver histology in subjects withnonalcoholic steatohepatitis. Clin J Am Soc Nephrol 5: 2166–2171CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, (2007) Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 357: 741–752CrossRefPubMedGoogle Scholar
  49. 49.
    Lassailly G, Caiazzo R, Buob, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P, (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterol 149: 379–388CrossRefGoogle Scholar
  50. 50.
    Hannah WN, Harrison SA, (2016) Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci 61: 1365–1374CrossRefPubMedGoogle Scholar
  51. 51.
    Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM, (2015) Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg 19: 429–436CrossRefPubMedGoogle Scholar
  52. 52.
    Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK, (2008) Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6: 1396–1402CrossRefPubMedGoogle Scholar
  53. 53.
    Ratziu V, (2016) Novel pharmacotherapy options for Nash. Dig Dis Sci 61: 1398–1405CrossRefPubMedGoogle Scholar
  54. 54.
    Laganà AS, Vitale SG, Nigro A, Sofo V, Salmeri FM, Rossetti P, Chiara Rapisarda AM, La Vignera S, Condorelli RS, Rizzo G, Buscema M, (2016) Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives Int J Mol Sci 17: pii:E999CrossRefPubMedGoogle Scholar
  55. 55.
    Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, on behalf of the GOLDEN-505 Investigator Study Group (2016) Elafibranor, an agonist of the peroxisome proliferator-activated receptor alpha and delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150: 1147–1159CrossRefPubMedGoogle Scholar
  56. 56.
    Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, (2015) NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385: 956–965CrossRefPubMedGoogle Scholar
  57. 57.
    Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team., Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN, (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled phase 2 study. Lancet 387: 679–690CrossRefPubMedGoogle Scholar
  58. 58.
    Lassailly G, Caiazzo R, Pattou F, Mathurin P, (2016) Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterol 150: 1835–1848CrossRefGoogle Scholar
  59. 59.
    Afzali A, Berry K, Ioannou GN, (2012) Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 18: 29–37CrossRefPubMedGoogle Scholar
  60. 60.
    Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y, (2014) Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12: 394–402CrossRefPubMedGoogle Scholar
  61. 61.
    Park CW, Tsai NT, Wong LL, (2011) Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 25: e606–11CrossRefGoogle Scholar
  62. 62.
    Fussner LA, Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD, (2014)Google Scholar
  63. 63.
    The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int 34: 1259–1266Google Scholar
  64. 64.
    Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A, (2010) Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 105: 613–620CrossRefPubMedGoogle Scholar
  65. 65.
    Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, Upton MP, Reyes JD, Perkins JD, (2010) The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 16: 874–884CrossRefPubMedGoogle Scholar

Copyright information

© Société de réanimation de langue française (SRLF) et Lavoisier 2016

Authors and Affiliations

  • M. Hachemi
    • 1
  • S. Benmakhlouf
    • 2
  • P. Prost
    • 3
  • N. Santolaria
    • 4
  • X. Tchenio
    • 5
  • N. Sedillot
    • 5
  • F. Zoulim
    • 2
  1. 1.Service d’anesthésie réanimation chirurgicalecentre hospitalier FleyriatBourg-en-BresseFrance
  2. 2.Département d’hépatogastroentérologie et maladies du foiehôpital de la Croix-Rousse, hospices civils de LyonLyonFrance
  3. 3.Service d’hépatogastroentérologiecentre hospitalier FleyriatBourg-en-BresseFrance
  4. 4.Service de pharmaciecentre hospitalier FleyriatBourg-en-BresseFrance
  5. 5.Service de réanimation polyvalentecentre hospitalier FleyriatBourg-en-BresseFrance

Personalised recommendations